The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2021 | COVID-19: impact on lung cancer treatment in the UK
Kathryn Banfill, MBChB, MRCP(UK), FRCR, Christie NHS Foundation Trust, Manchester, UK, gives an overview of changes in the management of patients with lung cancer who have been treated with radical radiotherapy during the first wave of the COVID-19 pandemic in the UK. Data from patients with stage I-III lung cancer is being collected in a central database to monitor the impacts of changes in treatment and to guide recommendations in the COVID-RT Lung project. So far, the project has reported that the diagnostic investigations of 14% of patients with lung cancer were affected by the COVID-19 pandemic, and 37% of patients had a change of therapy, the most common change being a reduced dose of radiotherapy. This video was recorded at the virtual European Lung Cancer Congress (ELCC) 2021.
